NeoTX Scientific Publications

Tumor Targeted Superantigen (TTS), Naptumomab Estafenatox (NAP), enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors.

Sagi Y, Pinsker M and Shahar M
Poster presentation at SITC Annual Meeting 2021
View the complete poster here

Abstract: Sagi Y, Shahar M, Pinsker M. 576 Tumor Targeted Superantigen (TTS), Naptumomab Estafenatox (NAP), enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors. Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.576 –
See the PDF here

Selective T cell Redirection Proteins (STR) Enhance the Anti-Tumor Activity of Checkpoint Inhibitors (CPIs) and can Lead to Long-Lasting Immunity Against the Tumor.
Azulay M, Lifshits S, Shany E, Friedmann A, Hedlund G and Shahar M.
Poster presentation at SITC Annual Meeting 2019.
View the complete poster here.

Naptumomab Estafenatox induces T cell recognition, turning anti-PD-1 unresponsive “cold” tumors into “hot” responsive tumors.
Azulay M, Lifshits S, Friedmann A, Hedlund G, Törngren M, Shahar M.
Poster presentation at AACR Annual Meeting 2018.
View the complete poster here.

Abstract: Meir Azulay, Sveta Lifshits, Adam Fridman, Gunnar Hedlund, Marie Törngren, Michal Shahar. Naptumomab Estafenatox induces T cell recognition, turning anti-PD-1 unresponsive “cold” tumors into “hot” responsive tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2712.
View the abstract here